Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorPeking University First Hospital

About this trial

To explore the efficacy of dCBT-I therapy for chronic insomnia among breast cancer survivors in China, we propose to conduct a randomized, parallel controlled clinical study in breast cancer survivors using a smartphone Chinese application (app) "resleep". Breast cancer survivors with chronic insomnia were recruited from our Breast Disease Center and externally, with the waiting group as a parallel control and the dCBT-I treatment group as an intervention group, in a 1:1 sample size. Intervention group (dCBT-I treatment group) will receive full self-help dCBT-I administered by smartphone APP for 6 weeks. The control group (waiting for treatment group) will not receive any additional interventions based on the original conventional treatment and will be followed up as planned, waiting for treatment.At the end of the 3-month follow-up, the decision to receive treatment was made according to the patient's wishes. The primary endpoint was the insomnia severity index (ISI) at the end of treatment and at 3 months of treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years.

Breast cancer diagnosed within 5 years

Stable disease at the end of acute treatment (surgery, radiotherapy, chemotherapy) while meeting: ≥ 1 month after surgery, ≥ 3 months after the end of last chemotherapy, and ≥ 3 months after the end of last radiotherapy if radiotherapy is required.

Satisfy the diagnostic criteria for chronic insomnia disorder according to the (International Classification of Sleep Disorders-the Third Edition, ICSD-3)[ and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5): problem with falling asleep or maintaining sleep for ≥3 months (≥3 times per week) with impaired daytime functioning, despite the availability of sleep opportunities.

Disqualifiers

New breast cancer progression, recurrence, or metastasis within 3 months, requiring new radiotherapy or immunotherapy regimen

Expected survival <12 months due to all causes

Presence of any of the following conditions: Concurrent active cancer or malignancy that is being treated other than breast cancer, shift work, alcohol abuse, substance abuse, significant suicidal ideation, bipolar disorder, aggressive behavior, mania, schizophrenia.

Presence of a diagnosed significant physical illness that interferes with sleep, such as cranial disease or trauma, cancer pain, unstable angina, uncontrolled cardiac insufficiency and severe respiratory distress due to various causes, etc.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Digital Cognitive Behavioral Therapy for Insomnia

    Behavioral

    a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP

Treatment groups

264 Participants
are divided into 2 treatment groups
Group A: dCBT-I groupExperimental treatment 1 intervention
Group B: the wait-list groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

The insomnia severity index (ISI) scores

Time frame
immediately post-treatment
2

The insomnia severity index (ISI) scores

Time frame
3-months follow-up

Secondary outcomes

1

The insomnia severity index (ISI) scores

Time frame
6-months follow-up
2

Online sleep diary measures

Online sleep diary measures(total sleep time, sleep efficiency, sleep latency, numbers and duration of awakenings during sleep)

Time frame
up to 6-months follow-up

Other outcomes

1

Generalized Anxiety Scale (GAD-7)

The GAD-7 is a simple and reliable anxiety screening tool. There are a total of seven questions with a score of 0-3 for each question. The total score provides a possible score from 0-21. A score of 10 or greater indicates further evaluation is required.

Time frame
up to 6-months follow-up
2

Patient Health Questionnaire-9 (PHQ-9)

The PHQ-9 is a simple and validated self-assessment scale for depressive disorders, with good reliability and validity both as an aid to the diagnosis of depression and in the assessment of symptom severity. It has a total of nine items with a total score of 0-27.

Time frame
up to 6-months follow-up
3

the Short-Form 12 Health Survey (SF-12)

The SF-12 is a simplified version of the quality of life questionnaire generated based on the SF-36 scale, consisting of 12 items, containing eight dimensions, and assessing an individual's perceived physical and mental health status. The scale is scored on a percentage scale, and after obtaining a crude score, it is converted using the standardized scoring method. It includes the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Higher scores indicate higher levels of quality of survival. 7)The smart bracelet data (recording parameters such as bedtime, sleep duration, number of awakenings during sleep, wake-up time, and sleep quality)

Time frame
up to 6-months follow-up
4

Pittsburgh sleep quality index (PSQI)

Time frame
up to 6-months follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University First Hospital

Lead sponsor

Shenzhen Zeen Health Technology Co., Ltd.

Collaborator